ZLABZai Lab Ltd
ZLAB
Zai Lab Ltd1,232
Mkt Cap
$2.09BVolume
1,634.0052W High
$44.3452W Low
$15.96PE Ratio
-11.48ZLAB Fundamentals
Price
$18.61Prev Close
$19.10Open
$18.3850D MA
$20.36Beta
1.12Avg. Volume
839,019.35EPS (Annual)
-$1.61P/B
3.12Rev/Employee
$258,617.15$1,366.81
Zai Lab Announces Changes to Senior Leadership Team
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company...
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the...
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2026, along with recent product highlights and corporate updates. We continue to accelerate the...
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight brokerages that are presently covering the firm...
Zai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor Call
Zai Lab (NASDAQ:ZLAB) hosted an investor call tied to the 2026 American Association for Cancer Research (AACR) meeting to highlight new data for its DLL3-targeted antibody-drug conjugate (ADC...
Zai Lab (NASDAQ:ZLAB) Trading Down 5.2% - Here's What Happened
Zai Lab (NASDAQ:ZLAB) Shares Down 5.2% - What's Next...
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its first quarter 2026 financial results and provide recent corporate updates on May 7, 2026, before the opening of U.S...
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31R Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from a preclinical study of ZL-1503, demonstrating that the companys internally developed IL-13/IL-31R bispecific antibody may lead...
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and...
<
1
2
...
>
Compact View
Not available
Not available